title: [Effects of SERMs on bone health. SERM and metabolic markers of bone].
abstract: Raloxifene is the only SERM available in Japan. The effect on bone metabolism is relatively mild and slow compared with that of bisphosphonates, and reaches plateau after 6th month or later. As diurnal variations of metabolic markers, especially urinary markers are large, it is often difficult to confirm the effect of raloxifen on bone by individual base. The strict sampling time before and after treatment, and/or selection of patients with high turnover bone may help to increase the chance to confirm the raloxifene effect. A new type of SERM bone marker such as tartrate resistant acid phosphatase fraction 5b is expected to improve the chance. Some papers suggest the relation between suppression of bone markers by raloxifene and vertebral fractures, but the relation is not usually confirmed due to wide variations of the markers.
authors.affiliation: Geriatric Medicine, Post Graduate School of Medicine, Osaka City University Medical School.
authors.forename: Miki
authors.initials: M
authors.lastname: Takami
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Shimada
mesh_terms: D000135:Acid Phosphatase / Q000097:blood; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects; D001862:Bone Resorption / Q000175:diagnosis; D001842:Bone and Bones / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004164:Diphosphonates / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes / Q000097:blood; D010024:Osteoporosis / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D020849:Raloxifene Hydrochloride / Q000494:pharmacology* / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000494:pharmacology* / Q000627:therapeutic use; D000071681:Tartrate-Resistant Acid Phosphatase
chemical_list: D015415:Biomarkers; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007527:Isoenzymes; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D000135:Acid Phosphatase; D000071681:Tartrate-Resistant Acid Phosphatase